Business Context and Reporting Period
Clearmind Medicine Inc., a foreign private issuer reporting on Form 20-F, filed this Form 6-K on October 8, 2026. The filing covers October 2026 and incorporates a press release titled “Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder.”
Financial and Operating Metrics
The filing text provides no revenue, profit, cash flow, margin, debt, liquidity, or other financial metrics. It does not provide a clear value for these items.
Changes Versus Prior Period
No comparable-period financial or operating results are reported, so changes versus a prior period cannot be assessed from this filing text.
Outlook, Risks, and Unusual Items
The filing text does not provide guidance, management commentary, risk disclosures, contingencies, or details about the patent publication beyond the press release title.
Important Facts to Verify
- Review Exhibit 99.1 for the patent publication’s scope, status, and any related claims or qualifications.
- Confirm whether the referenced patent publication creates any material commercial, regulatory, or financial implications; this filing text does not describe them.